从疫苗接种到报销的时间间隔:2021-2022年私营保险成人肺炎球菌结合疫苗接种的证据
研究利用2021-2022年MarketScan商业与Medicare数据库,分析19-64岁和≥65岁人群PCV13与PCV20门诊及药房接种索赔的报销间隔。结果显示新疫苗PCV20在ACIP推荐后5个月内报销间隔较长,约6个月后稳定至与PCV13相当;门诊和非都市区间隔更长。
要点
- 19-64岁门诊索赔平均报销间隔PCV13为25.3天,PCV20为26.8天。
- ≥65岁门诊索赔平均间隔PCV13为31.5天,PCV20为41.3天。
- 药房索赔间隔短于门诊索赔;非都市区门诊间隔长于都市区。
核心结论
- ACIP推荐后5个月内新疫苗PCV20报销间隔较长,约6个月后稳定至与PCV13相当的长度。
- 门诊和非都市区索赔报销间隔更长,推荐后数月部分索赔仍经历较长间隔。
研究设计与样本
- 使用2021-2022年Merative™ MarketScan®商业数据库和Medicare数据库(MarketScan)数据。
- 研究对象为19-64岁和≥65岁人群,分析PCV13(2012年推荐)和PCV20(2021年推荐)的接种索赔。
- 研究描述接种索赔、患者人口学特征及接种到报销的时间间隔。
主要发现
- 研究期间MarketScan®包含19-64岁个体PCV13门诊接种索赔24,508件、PCV20门诊接种索赔53,194件。
- 研究期间MarketScan®包含≥65岁个体PCV13索赔14,693件、PCV20索赔18,277件。
- 19-64岁门诊索赔平均报销间隔PCV13为25.3天,PCV20为26.8天。
- ≥65岁门诊索赔平均间隔PCV13为31.5天,PCV20为41.3天。
- 非都市区门诊索赔报销间隔长于都市区;药房索赔间隔短于门诊索赔(两种疫苗和两个年龄组均如此)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccination implementation challenges can lead to lower uptake, reducing health and economic benefits from vaccines. Healthcare provider confidence in receiving timely reimbursement for vaccination is one such potential challenge for newly recommended vaccines. This study investigates the time interval between pneumococcal vaccination and reimbursement. METHODS: We used 2021-2022 Merative™ MarketScan® Commercial Database and Medicare Database (MarketScan) data among those aged 19-64 and ≥65 years for two vaccines: the 13-valent pneumococcal conjugate vaccine (PCV13), recommended in 2012; and the newer 20-valent PCV (PCV20), recommended in 2021. We characterized vaccination claims, patient demographics, and time intervals between vaccination and reimbursement. RESULTS: During the study period, MarketScan® contained 24,508 PCV13 and 53,194 PCV20 outpatient vaccination claims for individuals aged 19-64 years and 14,693 PCV13 and 18,277 PCV20 claims for those aged ≥65 years. Among those aged 19-64 years, mean reimbursement interval of outpatient claims was 25.3 (PCV13) and 26.8 (PCV20) days. Among those aged ≥65 years, mean interval was longer, particularly for PCV20, with 31.5 (PCV13) and 41.3 days (PCV20). Outpatient claims reimbursement intervals were longer in non-metropolitan compared to metropolitan areas. Pharmacy claims had shorter intervals than outpatient claims, across both vaccines and age groups. PCV13 intervals were similar throughout the observation period, while PCV20 intervals were longer immediately following the updated ACIP recommendation and declined over time. Approximately 10 % of outpatient claims had intervals greater than 30 days among those aged 19-64 years and greater than 60 days for those aged ≥65 years. CONCLUSION: During the 5 months following the ACIP recommendation, claims for the newer vaccine (PCV20) took longer to reimburse, but the interval stabilized after about 6 months to a length comparable to PCV13. Claims from outpatient settings and non-metropolitan areas took longer to reimburse, with some claims still experiencing longer intervals several months post-recommendation.
引用
- Rosenblum HG, Carpenter CM, Trosclair T, et al. Time intervals from vaccine administration to reimbursement for an updated Advisory Committee on Immunization Practices (ACIP) recommendation: Evidence from pneumococcal conjugate vaccinations among privately insured adults, 2021-2022. Vaccine. 2025. PMID: 41014761. doi:10.1016/j.vaccine.2025.127665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。